Programme - Stepping Stone Symposium

Cancer & Neurodegenerative Diseases

20-22 June 2012, ETH Zurich, Switzerland


Day 1 – Wednesday, June 20

Time	Room	Cancer Research (CR)
08:00-09:00	Main Building (HG)	Registration, Welcome Coffee
09:00-09:20	Plenary Hall Auditorium E3	Welcome Ralph EICHLER (President ETH Zurich) Ken WU (Chinese Ambassador to Switzerland, Berne) Jürg BURRI (Deputy Director State Secretariat for Education and Research, Switzerland)
09:20-09:30		Introduction to the Symposium Wilhelm KREK (ETH Zurich) Adriano AGUZZI (University/University Hospital of Zurich)
Plenary I 09:30-10:15		Douglas HANAHAN (EPF Lausanne) Hallmarks of cancer: from concepts to new mechanistic insights
10:15-10:40	HG E Nordhof	Coffee Break
Parallel Session I (NDD)	HG D3.2	Neurodegenerative Diseases – Mechanism I Chair: Adriano AGUZZI
10:40-11:10		Adriano AGUZZI (University/University Hospital Zurich) Mechanisms of neurotoxicity in prion diseases
11:10-11:25		Tao WANG (IoN, Chinese Academy of Sciences) Protein SUMOylation in neurodegenerative diseases
11:25-11:45		Carolin SEURING (ETH Zurich) The mechanism of toxicity in HET-S/HET-s prion incompatibility
11:45-12:15		Guoxiang CHENG (Shanghai Transgenic Research Center) Production and characterization of PrP lacking goats
Parallel Session I (CR)	Plenary Hall Auditorium E3	Tumor Microenvironment and Metastasis Chair: Youyong LU
10:40-11:10		Haihe WANG (Sun Yat-Sen University) Roles of PRL-3 phosphatase in tumorigenesis and cancer metastasis
11:10-11:25		Yong CHEN (ETH Zurich) Identification of a selective inhibitor of melanoma stem cells by chemical library screening
11:25-11:55		Sabine WERNER (ETH Zurich) Role of activin in tissue repair and cancer
11:55-12:15		Xuebiao YAO (University of Science & Technology of China, Hefei) <i>Molecular dissection of cytokine CCL18-elicited breast cancer cell</i> <i>metastasis</i>

Day 1 – Wednesday, June 20

12:15-14:15	HG D Nordhof	Lunch + Poster Session
Parallel Session II (NDD)	HG D3.2	Neurodegenerative Diseases - Mechanism II Chair: Hansruedi LOETSCHER
14:15-14:30		Li ZHANG (Fudan University) The role of altered microRNA expression in hypoxia-activated microglia and microglia-mediated neuronal injury
14:30-14:45		Bin WEI (IBCB, Chinese Academy of Sciences) Mechanism with which GABA receptor controls the development of inflammation
14:45-15:15		Roland RIEK (ETH Zurich) <i>Structure activity relationship of protein aggregates in health and</i> <i>disease</i>
15:15-15:45		Jiawei ZHOU (IoN, Chinese Academy of Sciences) Suppression of neuroinflammation by dopamine D2
Parallel Session II (CR)	Plenary Hall Auditorium E3	Molecular Pathology and Biomarkers Chair: Bruno OSTERWALDER
14:15-14:45		Holger MOCH (University/University Hospital of Zurich) <i>Biobanking as prerequisite for personalized medicine</i>
14:45-15:15		Youyong LU (Peking University) A Novel Concept of SNVs Derived from Exomic Sequencing to Identify Frequent Mutations in Gastric Cancer
15:15-15:30		Chong XIE (Fudan University) <i>Multiplex quantification of autoantibody with PSA tests: a novel</i> <i>assay platform to improve conventional cancer biomarkers</i>
15:30-15:45		Ralph SCHIESS (Proteomedix Inc., Schlieren) Cancer genetics guided prostate cancer biomarkers
Plenary II 15:45-16.30	Plenary Hall Auditorium E3	Martin SCHWAB (University of Zurich/ETH Zurich) Repairing the hardware of the central nervous system after injury
16:30	HG E Nordhof	Apéro and Networking
18:30		Close-Door Dinner for Invited Speakers Restaurant "zum Grünen Glas" **

**Restaurant zum Grünen Glas, Untere Zäune 15, 8001 Zürich, 044 251 65 04; assembly at 18:10h in the main building next to the fountain.



Plenary Session Cancer Research Session Neuro Degenerative Disease Session

Day 2 – Thursday, June 21

Auditorium E3 Challenges of Basic and Translational Research in China Challenges of Basic and Huming P00 (Chinese Academy of Sciences, Shanghai) Coportion Internstity Muming P00 (Chinese Academy of Sciences, Shanghai) Challenges of Basic and Huming P00 (Chinese Academy of Sciences Internstity) Muming P00 (Chinese Academy of Sciences Internstity) Challenge Internstity <th></th> <th></th> <th></th>			
DB:30-09:15 Into the regulation of protein synthesis Joint Session Challenges of Basic and Translational Research in China Chair: Malo CHEN 09:15-09:45 Guoquiang CHEN (Shanghai Jiao Tong University, School of Medicine) Cancer research at Jiao Tong University 09:45-10:15 Muming POO (Chinese Academy of Sciences, Shanghai) Opportunities for neuroscience research in China 10:15-10:40 HG D Nordhof Coffee Break Parallel Session III (NDD) HG D3.2 Alzheimer Chair: Hilal LASHUEL Veidong LE (IoN, Shanghai Jiao Tong University) Hypoxia and Alzheimer's disease Weidong LE (IoN, Shanghai Jiao Tong University) Hypoxia and Alzheimer's diseases 11:40-11:40 Weidong LE (IoN, Shanghai Jiao Tong University) Hypoxia and Alzheimer's disease: Immunotherapy of neurodegenerative diseases 11:40-11:40 Kerson III (NDD) Kerson Alzheimer's disease: from preclinical models to clinical reality 12:10-12:40 Plenary Hall Auditorium E3 Cancer Cell Signaling Mechanisms Chair: Douglas HANAHAN 11:10-11:25 Veitelemer Ker (ETH Zurich) Feedback regulation of cancer signaling pathways: biologic and therapeutic implications 11:10-11:26 Jiangmei L1 (Institute of Biophysics, CAS, Beijing) PI4KII is a novel regulator of turnor growth by its action on angiogenesis and HIF1 regulation 11:10-11:25 Jiangmei L1 (Institute of Biophysi	Plenary III	Plenary Hall	Nenad BAN (ETH Zurich)
Joint Session Challenges of Basic and Translational Research in China Chair: Maio CHEN 09:15-09:45 Example of Chair: Maio Chener Medicine) Cancer research at Jiao Tong University 09:45-10:15 Muming POO (Chinese Academy of Sciences, Shanghai) Opportunities for neuroscience research in China 10:15-10:40 HG D Nordhof Coffee Break Parallel Session III (NDD) HG D3.2 Alzheimer Chair: Hilal LASHUEL Veidong LE (IoN, Shanghai Jiao Tong University) Hypoxia and Alzheimer's disease Weidong UE (IoN, Shanghai Jiao Tong University) Hypoxia and Alzheimer's disease 11:40-12:10 Weidong LE (IoN, Shanghai Jiao Tong University) Hypoxia and Alzheimer's disease: Immunotherapy of neurodegenerative diseases 11:40-12:10 Hasruedi LÖETSCHER (Roche, Basel) Immunotherapy in Alzheimer's disease: Innking cancer and neurodegeneration 12:10-12:40 Plenary Hall Auditorium E3 Cancer Cell Signaling Mechanisms Chair: Douglas HANAHAN 11:10-11:25 Vilhelm KREK (ETH Zurich) Feedback regulation of cancer signaling pathways: biologic and therapeutic implications 11:10-11:26 Vilhelm KREK (ETH Zurich) Feedback regulation of cancer signaling pathways: biologic and therapeutic implications 11:10-11:27 Jiangmei LI (Institute of Biophysics, CAS, Beijing) PI4KII is a novel regulator of tumor growth by its action on angiogenesis and HIF1 regulation 11:10-11:26	00.20 00.15	Auditorium ES	
Session Chair: Maio CHEN 09:15-09:45 Guoquiang CHEN (Shanghai Jiao Tong University, School of Medicine) Cancer research at Jiao Tong University 09:45-10:15 Muming POO (Chinese Academy of Sciences, Shanghai) Opportunities for neuroscience research in China 10:15-10:40 HG D Nordhof Coffee Break Parallel Session III (NDD) HG D3.2 Alzheimer Chair: Hilal LASHUEL 10:40-11:10 HG D3.2 Alzheimer Chair: Hilal LASHUEL 11:40-12:10 Hansruedi LÖETSCHER (Roche, Basel) Immunotherapy of neurodegenerative diseases: Inking cancer and neurodegeneration 11:40-12:10 Plenary Hall Auditorium E3 Cancer Cell Signaling Mechanisms Chair: Douglas HANAHAN (CR) Nuditorium E3 Cancer Cell Signaling Mechanisms Chair: Douglas HANAHAN 11:40-12:10 Jiangmei LI (Institute of Biophysics, CAS, Beijing) PI4KI/I is a novel regulator of tumor growth by its action on angiogenesis and HIF1 regulation 11:40-12:10 Bogdan MATEESCU (ETH Zurich) miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress signaling pathways 11:40-12:40 Anse MÜELLER (University of Zurich) miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress signaling pathways 11:40-12:40 Anse MÜELLER (University of Zurich) miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative str		-	Challen was of Resis and Translational Research in China
Medicine) Medicine) 09:45-10:15 Medicine) 09:45-10:15 Muming POO (Chinese Academy of Sciences, Shanghai) Opportunities for neuroscience research in China 10:15-10:40 HG D Nordhof Coffee Break Parallel Session III (NDD) HG D3.2 Alzheimer Chair: Hilal LASHUEL Weidong LE (IoN, Shanghai Jiao Tong University) Hypoxia and Alzheimer's disease Minimum China and Alzheimer's diseases 11:40-12:10 Weidong LE (IoN, Shanghai Jiao Tong University) Hypoxia and Alzheimer's diseases Minimum China and Alzheimer's diseases 11:40-12:10 Weidong LE (IoN, Shanghai Jiao Tong University) Hypoxia and Alzheimer's diseases: from preclinical models to clinical reality 12:10-12:40 Lawrence RAJENDRAN(University of Zurich) Role of AKT proteins in Alzheimer's disease: linking cancer and neurodegeneration Parallel Session III (CR) Plenary Hall Auditorium E3 Cancer Cell Signaling Mechanisms Chair: Douglas HANAHAN 11:40-11:10 Nilheim KREK (ETH Zurich) Feedback regulator of tumor growth by its action on angiogenesis and HIF1 regulation 11:25-11:40 Bogdan MATEESCU (ETH Zurich) miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress signaling pathways 11:40-12:10 Anne MÜELLER (University of Zurich) Systemic microRNA-34a replacement therapy for the treatment of diffuse large B-cell lymphoma	Session		
Opportunities for neuroscience research in China 10:15-10:40 HG D Nordhof Coffee Break Parallel Session III (NDD) HG D 3.2 Alzheimer Chair: Hilal LASHUEL 10:40-11:10 Weidong LE (IoN, Shanghai Jiao Tong University) Hypoxia and Alzheimer's disease 11:10-11:40 Roger NITSCH (University of Zurich) Immunotherapy of neurodegenerative diseases 11:40-12:10 Hansruedi LÖETSCHER (Roche, Basel) Immunotherapy of neurodegenerative disease: from preclinical models to clinical reality 12:10-12:40 Plenary Hall Auditorium E3 Cancer Cell Signaling Mechanisms Chair: Douglas HANAHAN 10:40-11:10 Nilhelm KREK (ETH Zurich) Feedback regulation of cancer signaling pathways: biologic and therapeutic implications 11:10-11:25 Jiangmei LI (Institute of Biophysics, CAS, Beijing) PI4KII is a novel regulator of tumor growth by its action on angiogenesis and HIF1 regulation 11:40-12:10 Bogdan MATEESCU (ETH Zurich) Feedback regulation of cancer signaling pathways: biologic and therapeutic implications 11:40-12:10 Anne MÜELLER (University of Zurich) Systemic microRNA-34a replacement therapy for the treatment of diffuse large B-cell lymphoma 12:10-12:40 HG D Nordhof Poster + Lunch 14:40 Visiting Programme: University of Zurich, Irchel campus, Science City, ETH Zurich ***	09:15-09:45	_	Medicine)
Parallel Session III (NDD) HG D3.2 Alzheimer Chair: Hilal LASHUEL 10:40-11:10 HG D3.2 Alzheimer Chair: Hilal LASHUEL 11:10-11:40 Weidong LE (IoN, Shanghai Jiao Tong University) Hypoxia and Alzheimer's diseases 11:10-11:40 Roger NITSCH (University of Zurich) Immunotherapy of neurodegenerative diseases 11:40-12:10 Hansruedi LÖETSCHER (Roche, Basel) Immunotherapy in Alzheimer's disease: from preclinical models to clinical reality 12:10-12:40 Plenary Hall Auditorium E3 Cancer Cell Signaling Mechanisms Chair: Douglas HANAHAN 10:40-11:10 Vilhelm KREK (ETH Zurich) Feedback regulation of cancer signaling pathways: biologic and therapeutic implications 11:10-11:25 Jiangmei LI (Institute of Biophysics, CAS, Beijing) PI4KI is a novel regulation of varien tumorigenesis by controlling oxidative stress signaling pathways: biologic and therapeutic implications 11:25-11:40 Bogdan MATEESCU (ETH Zurich) For Multi Sa movel regulation of varien tumorigenesis by controlling oxidative stress signaling pathways 11:40-12:10 Dong XIE (CAS, Shanghai) EphB mediates kinase-dependent suppression of lung cancer metastasis via a PP2A/RACK1/AKT signaling complex 12:40-14:40 HG D Nordhof Poster + Lunch	09:45-10:15		
Session III (NDD) Chair: Hilal LASHUEL 10:40-11:10 Weidong LE (IoN, Shanghai Jiao Tong University) Hypoxia and Alzheimer's disease 11:10-11:40 Roger NITSCH (University of Zurich) Immunotherapy of neurodegenerative diseases 11:40-12:10 Hansruedi LÖETSCHER (Roche, Basel) Immunotherapy in Alzheimer's disease: from preclinical models to clinical reality 12:10-12:40 Lawrence RAJENDRAN(University of Zurich) Role of AKT proteins in Alzheimer's disease: linking cancer and neurodegeneration Parallel Session III (CR) Plenary Hall Auditorium E3 Chair: Douglas HANAHAN 10:40-11:10 Wilhelm KREK (ETH Zurich) Feedback regulation of cancer signaling pathways: biologic and therapeutic implications 11:10-11:25 Jiangmei LI (Institute of Biophysics, CAS, Beijing) PleKHI is a novel regulator of tumor growth by its action on angiogenesis and HIF1 regulation 11:25-11:40 Bogdan MATEESCU (ETH Zurich) miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress signaling pathways 11:40-12:10 Anne MÜELLER (University of Zurich) Systemic microRNA-34a replacement therapy for the treatment of diffuse large B-cell lymphoma 12:10-12:40 HG D Nordhof Poster + Lunch 14:40 Visiting Programme: University of Zurich, Irchel campus, Science City, ETH Zurich ***	10:15-10:40	HG D Nordhof	Coffee Break
Hypoxia and Àlzheimer's disease Hypoxia and Àlzheimer's disease 11:10-11:40 Roger NITSCH (University of Zurich) Immunotherapy of neurodegenerative diseases 11:40-12:10 Hansruedi LÖETSCHER (Roche, Basel) Immunotherapy in Alzheimer's disease: from preclinical models to clinical reality 12:10-12:40 Lawrence RAJENDRAN(University of Zurich) Role of AKT proteins in Alzheimer's disease: linking cancer and neurodegeneration Parallel Session III (CR) Plenary Hall Auditorium E3 Cancer Cell Signaling Mechanisms Chair: Douglas HANAHAN 10:40-11:10 Wilhelm KREK (ETH Zurich) Feedback regulation of cancer signaling pathways: biologic and therapeutic implications 11:10-11:25 Jiangmei LI (Institute of Biophysics, CAS, Beijing) PI4KII is a novel regulator of tumor growth by its action on angiogenesis and HIF1 regulation 11:25-11:40 Bogdan MATEESCU (ETH Zurich) miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress signaling pathways 11:40-12:10 Dong XIE (CAS, Shanghai) EphB3 mediates kinase-dependent suppression of lung cancer metastasis via a PP2A/RACK1/AKT signaling complex 12:40-14:40 HG D Nordhof Poster + Lunch 14:40 Visiting Programme: University of Zurich, Irchel campus, Science City, ETH Zurich ***	Parallel Session III (NDD)	HG D3.2	
Immunotherapy of neurodegenerative diseases 11:40-12:10 Immunotherapy in Alzheimer's disease: from preclinical models to clinical reality 12:10-12:40 Lawrence RAJENDRAN(University of Zurich) Role of AKT proteins in Alzheimer's disease: linking cancer and neurodegeneration Parallel Session III (CR) Plenary Hall Auditorium E3 (CR) Cancer Cell Signaling Mechanisms Chair: Douglas HANAHAN 10:40-11:10 Wilhelm KREK (ETH Zurich) Feedback regulation of cancer signaling pathways: biologic and therapeutic implications 11:10-11:25 Jiangmei LI (Institute of Biophysics, CAS, Beijing) Pl4KII is a novel regulation of tumor growth by its action on angiogenesis and HIF1 regulation 11:25-11:40 Bogdan MATEESCU (ETH Zurich) miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress signaling pathways 11:40-12:10 Dong XIE (CAS, Shanghai) EphB3 mediates kinase-dependent suppression of lung cancer metastasis via a PP2A/RACK1/AKT signaling complex 12:40-14:40 HG D Nordhof Poster + Lunch 14:40 Visiting Programme: University of Zurich, Irchel campus, Science City, ETH Zurich ***	10:40-11:10	-	
Immunotherapy in Alzheimer's disease: from preclinical models to clinical reality 12:10-12:40 Lawrence RAJENDRAN(University of Zurich) Role of AKT proteins in Alzheimer's disease: linking cancer and neurodegeneration Parallel Session III (CR) Plenary Hall Auditorium E3 Cancer Cell Signaling Mechanisms Chair: Douglas HANAHAN 10:40-11:10 Wilhelm KREK (ETH Zurich) Feedback regulation of cancer signaling pathways: biologic and therapeutic implications 11:10-11:25 Jiangmei LI (Institute of Biophysics, CAS, Beijing) Pl4KlI is a novel regulator of tumor growth by its action on angiogenesis and HIF1 regulation 11:25-11:40 Bogdan MATEESCU (ETH Zurich) Feedback regulation of varian tumorigenesis by controlling oxidative stress signaling pathways 11:40-12:10 Anne MÜELLER (University of Zurich) Systemic microRNA-34a replacement therapy for the treatment of diffuse large B-cell lymphoma 12:10-12:40 HG D Nordhof Poster + Lunch 14:40 Visiting Programme: University of Zurich, Irchel campus, Science City, ETH Zurich ***	11:10-11:40	-	
Role of AKT proteins in Alzheimer's disease: linking cancer and neurodegenerationParallel Session III (CR)Plenary Hall Auditorium E3Cancer Cell Signaling Mechanisms Chair: Douglas HANAHAN10:40-11:10 11:40-11:125Wilhelm KREK (ETH Zurich) Feedback regulation of cancer signaling pathways: biologic and therapeutic implications11:10-11:25 11:25-11:40Wilhelm KREK (ETH Zurich) Feedback regulation of cancer signaling pathways: biologic and therapeutic implications11:25-11:40 11:25-11:40Bogdan MATEESCU (ETH Zurich) miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress signaling pathways11:40-12:10 12:10-12:40Dong XIE (CAS, Shanghai) EphB3 mediates kinase-dependent suppression of lung cancer metastasis via a PP2A/RACK1/AKT signaling complex12:40-14:40HG D NordhofPoster + Lunch14:40Visiting Programme: University of Zurich, Irchel campus, Science City, ETH Zurich ***	11:40-12:10	-	Immunotherapy in Alzheimer's disease: from preclinical models to
Session III (CR)Auditorium E3Chair: Douglas HANAHAN10:40-11:10Wilhelm KREK (ETH Zurich) Feedback regulation of cancer signaling pathways: biologic and therapeutic implications11:10-11:25Jiangmei LI (Institute of Biophysics, CAS, Beijing) PI4KII is a novel regulator of tumor growth by its action on angiogenesis and HIF1 regulation11:25-11:40Bogdan MATEESCU (ETH Zurich) miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress signaling pathways11:40-12:10Anne MÜELLER (University of Zurich) Systemic microRNA-34a replacement therapy for the treatment of diffuse large B-cell lymphoma12:10-12:40HG D Nordhof14:40Visiting Programme: University of Zurich, Irchel campus, Science City, ETH Zurich ***	12:10-12:40		Role of AKT proteins in Alzheimer's disease: linking cancer and
Feedback regulation of cancer signaling pathways: biologic and therapeutic implications11:10-11:2511:10-11:2511:25-11:4011:25-11:4011:40-12:1011:40-12:1012:10-12:4012:10-12:40HG D NordhofPoster + Lunch14:40Visiting Programme: University of Zurich, Irchel campus, Science City, ETH Zurich ***	Parallel Session III (CR)	Auditorium E3	
PI4KII is a novel regulator of tumor growth by its action on angiogenesis and HIF1 regulation11:25-11:40Bogdan MATEESCU (ETH Zurich) miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress signaling pathways11:40-12:10Anne MÜELLER (University of Zurich) Systemic microRNA-34a replacement therapy for the treatment of diffuse large B-cell lymphoma12:10-12:40Dong XIE (CAS, Shanghai) EphB3 mediates kinase-dependent suppression of lung cancer metastasis via a PP2A/RACK1/AKT signaling complex12:40-14:40HG D NordhofPoster + Lunch14:40Visiting Programme: University of Zurich, Irchel campus, Science City, ETH Zurich ***	10:40-11:10		Feedback regulation of cancer signaling pathways: biologic and
miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress signaling pathways11:40-12:10Anne MÜELLER (University of Zurich) Systemic microRNA-34a replacement therapy for the treatment of diffuse large B-cell lymphoma12:10-12:40Dong XIE (CAS, Shanghai) EphB3 mediates kinase-dependent suppression of lung cancer metastasis via a PP2A/RACK1/AKT signaling complex12:40-14:40HG D NordhofPoster + Lunch14:40Visiting Programme: University of Zurich, Irchel campus, Science City, ETH Zurich ***	11:10-11:25		PI4KII is a novel regulator of tumor growth by its action on
12:10-12:40 Systemic microRNA-34a replacement therapy for the treatment of diffuse large B-cell lymphoma 12:10-12:40 Dong XIE (CAS, Shanghai) EphB3 mediates kinase-dependent suppression of lung cancer metastasis via a PP2A/RACK1/AKT signaling complex 12:40-14:40 HG D Nordhof 14:40 Visiting Programme: University of Zurich, Irchel campus, Science City, ETH Zurich ***	11:25-11:40		miR-141 and miR-200a act on ovarian tumorigenesis by controlling
EphB3 mediates kinase-dependent suppression of lung cancer metastasis via a PP2A/RACK1/AKT signaling complex 12:40-14:40 HG D Nordhof Poster + Lunch 14:40 Visiting Programme: University of Zurich, Irchel campus, Science City, ETH Zurich ***	11:40-12:10		Systemic microRNA-34a replacement therapy for the treatment of
14:40 Visiting Programme: University of Zurich, Irchel campus, Science City, ETH Zurich ***	12:10-12:40		EphB3 mediates kinase-dependent suppression of lung cancer
Science City, ETH Zurich ***	12:40-14:40	HG D Nordhof	Poster + Lunch
18:00 Conference Banquet: Restaurant "Die Waid"	14:40		
	18:00		Conference Banquet: Restaurant "Die Waid"

Day 3 – Friday, June 22

		1
Plenary IV	Plenary Hall Auditorium E3	Muming POO (Chinese Academy of Sciences, Shanghai)
08:30-09:15		Regulation of neural plasticity by neurotrophins
Parallel Session IV.I (NDD)	HG D3.2	Chair: Christian LUESCHER
09:15-09:45		Andreas PAPASSOTIROPOULOS (University of Basel) Human genetics- and imaging-driven identification of memory modulating drugs
09:45-10:00		Annika ARMULIK (University/University Hospital Zurich) <i>Pericytes-gatekeeps at the neurovascular unit</i>
10:00-10:15		Thomas WÄLCHLI (University of Zurich/ETH Zurich) Nogo-A is a negative regulator of CNS angiogenesis
Parallel Session IV.I (CR)	Plenary Hall Auditorium E3	Translational Research and Drug Discovery Chair: Holger MOCH
09:15-09:45		Francesco HOFMANN (Novartis, Basel) New avenues in targeted anti-cancer therapy
09:45-10:15		Oliver HANTSCHEL (EPF Lausanne) Signaling mechanisms of Abl oncoproteins in human leukemia
10:15-10:45	HG E Nordhof	Coffee Break
Parallel Session IV:II (NDD)	HG D3.2	Chair: Muming POO
10:45-11:15		Hilal LASHUEL (EPF Lausanne) Structure basis of amyloid toxicity in Alzheimer's and Parkinson's disease
11:15-11:30		Anne SCHUETZ (ETH Zurich) Amyloid-ligand interactions studied at atomic resolution
11:30-12:00		Yan ZHANG (Beijing University) GABA down regulates uptake of amyloid β by hippocampus neurons, which reduces toxicity of intracellular A β and improves cognitive impairment
12:00-12:15		Johannes SARNTHEIN (University Hospital Zurich) DBS in Parkinson's disease: localization of stimulation sites based on a mean 3-dimensional atlas of the basal ganglia
12:15-12:45		Christian LÜSCHER (University of Geneva) Drug-evoked synaptic plasticity: a permissive switch to alter behavior
Parallel Session IV.II (CR)	Plenary Hall Auditorium E3	Translational Research and Drug Discovery Chair: Holger MOCH
10:45-11:15		Nancy HYNES (Friedrich Miescher Institute, Basel) Targeting receptor tyrosine kinases for breast cancer therapy
11:15-11:45		Andrea ALIMONTI (Institute of Oncology Research, Bellinzona) <i>Manipulation of cellular senescence pathways for cancer therapy</i>

Day 3 – Friday, June 22

-	-	
11:45-12:15	Plenary Hall Auditorium E3	Bruno OSTERWALDER (Merck-Serono, Geneva) How can we more efficiently translate our increasing biological understanding of cancer into clinically relevant novel treatments?
12:15-12:45		YongZhang LUO (Tsinghua University, Beijing) <i>Targeting vasculatures in tumor microenvironment and pre-</i> <i>metastasis niche</i>
12:45-13:10	Plenary Hall Auditorium E3	Concluding Remarks Wilhelm KREK (ETH Zurich) Adriano AGUZZI (University/University Hospital of Zurich)
		Thank You and Farewell Andreas FISCHER (Rector, University of Zurich)
13:10	HG E Nordhof	Sandwich Lunch and Departure
13:30-14:50	HG E42 Pallmann-Room	Close-Door Discussion : Future Sino-Swiss cooperation in drug discovery